Preventing Stroke, Premature Death and Cognitive Decline in a Broader Community of Patients With Atrial Fibrillation

PHASE4RecruitingINTERVENTIONAL
Enrollment

3,000

Participants

Timeline

Start Date

June 1, 2021

Primary Completion Date

December 31, 2027

Study Completion Date

January 31, 2031

Conditions
Atrial Fibrillation
Interventions
DRUG

Direct Oral Anticoagulants

choice of DOAC (apixaban, dabigatran, edoxaban or rivaroxaban) according to local practice

Trial Locations (1)

B15 2TH

RECRUITING

University Hospitals Birmingham, Birmingham

Sponsors
All Listed Sponsors
collaborator

Clinical Practice Research Datalink

OTHER_GOV

collaborator

University Hospital Birmingham NHS Foundation Trust

OTHER

collaborator

University of Oxford

OTHER

collaborator

London School of Economics and Political Science

OTHER

collaborator

Aston University

OTHER

lead

University of Birmingham

OTHER